Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

  • Background: Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients. Methods: A total of 155 patients with BRAF-mutated melanoma from 17 European skin cancer centres were retrospectively analysed. Out of these, 87 patients received concomitant radiotherapy and BRAFi (59 vemurafenib, 28 dabrafenib), while in 68 patients BRAFi therapy was interrupted during radiation (51 vemurafenib, 17 dabrafenib). Overall survival was calculated from the first radiation (OSRT) and from start of BRAFi therapy (OSBRAFi). Results: The median duration of BRAFi treatment interruption prior to radiotherapy was 4 days and lasted for 17 days. Median OSRT and OSBRAFi in the entire cohort were 9.8 and 12.6 months in the interrupted group and 7.3 and 11.5 months in the concomitant group (P=0.075/P=0.217), respectively. Interrupted vemurafenib treatment with a median OSRT and OSBRAFi of 10.1 and 13.1 months, respectively, was superior to concomitant vemurafenib treatment with a median OSRT and OSBRAFi of 6.6 and 10.9 months (P=0.004/P=0.067). Interrupted dabrafenib treatment with a median OSRT and OSBRAFi of 7.7 and 9.8 months, respectively, did not differ from concomitant dabrafenib treatment with a median OSRT and OSBRAFi of 9.9 and 11.6 months (P=0.132/P=0.404). Median local control of the irradiated area did not differ in the interrupted and concomitant BRAFi treatment groups (P=0.619). Skin toxicity of grade ≥2 (CTCAE) was significantly increased in patients with concomitant vemurafenib compared to the group with treatment interruption (P=0.002). Conclusions: Interruption of vemurafenib treatment during radiation was associated with better survival and less toxicity compared to concomitant treatment. Due to lower number of patients, the relevance of treatment interruption in dabrafenib treated patients should be further investigated. The results of this analysis indicate that treatment with the BRAFi vemurafenib should be interrupted during radiotherapy. Prospective studies are desperately needed.
Metadaten
Author:Markus HechtORCiDGND, Friedegund MeierGND, Lisa Zimmer, Bülent Polat, Carmen LoquaiGND, Carsten Weishaupt, Andrea Forschner, Ralf Gutzmer, Jochen Utikal, Simone M. Goldinger, Michael Geier, Jessica C. Hassel, Panagiotis BalermpasORCiDGND, Felix Kiecker, Ricarda Rauschenberg, Ursula Dietrich, Patrick Clemens, Carola Berking, Gerhard Grabenbauer, Dirk Schadendorf, Stephan Grabbe, Gerold Schuler, Rainer FietkauORCiDGND, Luitpold Valentin Rudolf Distel, Lucie HeinzerlingGND
URN:urn:nbn:de:hebis:30:3-502423
DOI:https://doi.org/10.1038/bjc.2017.489
ISSN:1532-1827
ISSN:0007-0920
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/29438368
Parent Title (English):British journal of cancer
Publisher:Nature Publ. Group
Place of publication:Edinburgh
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/02/13
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2019/05/13
Tag:BRAF; dabrafenib; radiation; radiotherapy; vemurafenib
Volume:118
Issue:6
Page Number:8
First Page:785
Last Page:792
Note:
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
HeBIS-PPN:452460417
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung-Keine kommerzielle Nutzung-Weitergabe unter gleichen Bedingungen